Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Brian Keith Law
Novel Agents That Downregulate EGFR, HER2, and HER3 in Parallel
Oncotarget
Oncology
Related publications
Author Correction: HER Kinase Inhibition in Patients With HER2- And HER3-mutant Cancers
Nature
Multidisciplinary
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Clinical Cancer Research
Cancer Research
Oncology
EGFR and HER2 Signaling in Breast Cancer Brain Metastasis
Frontiers in Bioscience - Elite
Immunology
Molecular Biology
Biochemistry
Microbiology
Medicine
Genetics
Pd28-09 Abnormal Her2 and Her3 Signalling in Prostate Cancer: Potentials for Clinical Application.
Journal of Urology
Urology
EGFR and HER2 Expression in Advanced Biliary Tract Cancer
Zeitschrift fur Gastroenterologie
Medicine
Gastroenterology
HER2-HER3 Dimer Quantification by FLIM-FRET Predicts Breast Cancer Metastatic Relapse Independently of HER2 IHC Status
Oncotarget
Oncology
Positive Prognostic Value of HER2-HER3 Co-Expression and P-mTOR in Gastric Cancer Patients
BMC Cancer
Cancer Research
Oncology
Genetics
NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies
Oxidative Medicine and Cellular Longevity
Biochemistry
Medicine
Cell Biology
Aging
Inhibition of EGFR, HER2, and HER3 Signalling in Patients With Colorectal Cancer Wild-Type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): A Phase 2–3 Randomised Trial
Lancet Gastroenterology and Hepatology, The
Hepatology
Gastroenterology
